Financial Performance - As of December 31, 2025, Arbutus had cash, cash equivalents, and marketable securities totaling $91.5 million, down from $122.6 million in 2024[6]. - Total revenue for the year ended December 31, 2025, was $14.1 million, a significant increase from $6.2 million in 2024, primarily due to the recognition of previously deferred revenue[7]. - The net loss for the year ended December 31, 2025, was $33.5 million, or a loss of $0.17 per share, compared to a net loss of $69.9 million, or a loss of $0.38 per share, in 2024[10]. Expenses Management - Research and development expenses decreased to $25.2 million in 2025 from $54.0 million in 2024, reflecting cost-saving measures[8]. - General and administrative expenses were reduced to $15.9 million in 2025 from $22.1 million in 2024, driven by cost-cutting efforts[9]. Milestones and Payments - Arbutus received a milestone payment of $0.5 million in December 2025 related to Alnylam's use of its proprietary LNP technology[5]. - The settlement with Moderna includes a $950 million upfront payment and an additional $1.3 billion contingent payment, with Arbutus entitled to 20% of the upfront payment after litigation costs[4]. Clinical Trials and Development - A total of 10 patients have achieved functional cure in Phase 2a clinical trials of imdusiran, with two additional patients achieving this status recently[4]. - Arbutus continues to support Genevant in ongoing patent litigation against Pfizer/BioNTech regarding the use of its patented LNP technology[4]. - Arbutus has made numerous assumptions regarding the effectiveness and timeliness of clinical trials, which are subject to significant uncertainties[22]. - Ongoing and anticipated clinical trials may incur higher costs or take longer than expected, potentially affecting product development[22]. - Regulatory approvals for clinical development of product candidates are uncertain and may not be obtained[22]. Strategic Considerations - The company is evaluating a potential return of capital to shareholders in Q3 2026 following the receipt of the noncontingent payment from Moderna[5]. - Arbutus may change its strategy regarding product candidates and clinical development activities based on market conditions[22]. - Market shifts may necessitate a change in strategic focus for Arbutus[22]. - Workforce reduction plans aim to decrease net cash burn but may not significantly extend the cash runway[22]. Risk Factors - The company faces risks related to the sufficiency of cash resources for foreseeable and unforeseeable operating expenses[22]. - Known risk factors include potential litigation and patent litigation uncertainties[22]. - Economic and market conditions may worsen, impacting overall business performance[22]. - Arbutus disclaims any obligation to revise or update forward-looking statements unless required by law[23].

Drug Development and Clinical Trials - Arbutus Biopharma is developing imdusiran (AB-729) and AB-101 for chronic hepatitis B (cHBV) treatment[26]. - In Phase 2a trials, 47% (49/105) of patients achieved functional cure or remained off nucleos(t)ide analogue therapy after treatment with imdusiran[36]. - Imdusiran has shown meaningful reductions in HBsAg and other viral proteins, leading to functional cure in some patients[34]. - The IM-PROVE I trial showed a functional cure rate of 50% (3/6) in HBeAg negative patients with baseline HBsAg levels <1000 IU/mL[37]. - AB-101 is currently in a Phase 1a/1b clinical trial, showing it was generally well-tolerated with evidence of high receptor occupancy[35]. - In the IM-PROVE I Phase 2a trial, 37% (16/43) of patients either achieved functional cure or remained off NA therapy for at least 48 weeks after treatment with imdusiran[50]. - The IM-PROVE II trial showed that 25% (3/12) of patients achieved functional cure, with 50% (3/6) of patients having baseline HBsAg <1000 IU/mL achieving this outcome[53]. - The addition of low dose nivolumab in the IM-PROVE II trial increased HBsAg seroclearance rates to 23% (3/13) by week 48[54]. - In the Phase 1b trial for imdusiran, 71% (44/62) of patients achieved HBsAg levels below 100 IU/mL, with 5% (3/62) achieving HBsAg seroclearance[58]. - The treatment with AB-101 was well-tolerated, showing no serious adverse events or liver dysfunction in patients[63]. - The clinical trial process is expensive and time-consuming, with outcomes uncertain, and delays could harm the company's financial condition and prospects[205]. - Regulatory approval processes are time-consuming and unpredictable, and the company may fail to obtain necessary approvals for its product candidates[220]. - The company must demonstrate the safety and efficacy of its product candidates through extensive clinical testing, which requires significant investment and carries inherent risks[208]. - Compliance with GLP and GCP regulations is essential for controlled research and human clinical testing[223]. - Regulatory approval may be delayed or prevented due to clinical trial challenges, impacting financial position[224]. - Difficulties in patient enrollment for clinical trials could delay the testing of product candidates[225]. - Side effects may lead to stronger product warnings and costly post-marketing studies, affecting commercial viability[224]. - Failure to demonstrate safety and efficacy in clinical trials could result in denial of marketing approval[223]. - Inadequacies in third-party manufacturing processes may adversely affect product candidates[223]. - The need for Risk Evaluation and Mitigation Strategy (REMS) could arise from undesirable side effects[224]. - Disagreements with regulatory authorities regarding clinical data interpretation may hinder approval processes[223]. - The commercial viability of approved products may be limited by undesirable side effects[224]. - The timing of clinical trials is dependent on the speed of patient recruitment[225]. Financial and Strategic Partnerships - Moderna will make a $950 million noncontingent payment to Arbutus and Genevant by July 8, 2026, with an additional contingent payment of $1.3 billion possible[28]. - In 2025, Arbutus reduced its workforce by 40% and incurred one-time restructuring charges of $12.9 million[28]. - The company is exploring strategic alliances to accelerate the development of its pipeline programs[44]. - Qilu Pharmaceutical Co., Ltd. made a one-time upfront cash payment of $40 million and agreed to pay up to $245 million upon achieving certain milestones related to imdusiran[65]. - Qilu is responsible for all costs related to the development and commercialization of imdusiran in Greater China and Taiwan, with a joint development committee established to coordinate efforts[66]. - The company recognized all previously deferred revenue in Q2 2025 after mutually agreeing to terminate the Qilu License Agreement, regaining global rights for imdusiran[69]. - Alnylam's ONPATTRO generates tiered royalty payments for the company, ranging from 1.00% to 2.33% on global net sales, with the highest tier applicable to sales above $500 million[71]. - The company received $0.5 million in December 2025 for achieving a contractual milestone related to Alnylam's use of its LNP technology in a new product candidate[73]. - The company is involved in ongoing patent infringement lawsuits against Pfizer/BioNTech and potentially Moderna, requiring substantial resource investment[186]. - The potential additional payments related to the acquisition of Enantigen Therapeutics could reach up to $102.5 million in sales performance milestones, plus a low single-digit royalty on net sales of the first commercialized HBV product[94]. - The company has $91.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025[192]. - The Moderna Settlement Agreement includes a Noncontingent Settlement Payment of $950 million and a Contingent Settlement Payment of up to $1.3 billion, dependent on specific legal outcomes[187]. Regulatory and Compliance Challenges - The company is committed to complying with all applicable laws and regulations, which is crucial for the successful development and commercialization of its products[114]. - The FDA generally provides for action on a New Drug Application (NDA) within 10 months of the 60-day filing date, or within 12 months of the NDA submission[129]. - For product candidates granted priority review designation, the targeted action date can be shortened to 6 months of the 60-day filing date, or 8 months after NDA submission[130]. - The FDA may require post-approval studies to be underway prior to Accelerated Approval or within a specified time from the date of approval[131]. - The maximum period of patent term restoration is five years, and the patent cannot be extended to more than 14 years from the date of FDA approval of the product[137]. - In the European Union, new medicinal products are granted a protection period of eight years of data exclusivity and an additional two years of market exclusivity[138]. - A proposal to reform the EU regulatory data protection system suggests a total of nine years of protection, with the possibility of obtaining up to 11 years under certain circumstances[139]. - Once approved, drug products are subject to ongoing monitoring for safety information and may face regulatory actions if safety problems occur post-market[140]. - The FDA may convene an advisory committee to seek insights and recommendations on issues relevant to the approval of an NDA[132]. - The FDA's interpretation of clinical trial data may differ from the sponsor's, which can affect the approval process[132]. - The FDA can conduct audits to determine if clinical trials were conducted in compliance with Good Clinical Practice (GCP) regulations[132]. - Companies must comply with Good Manufacturing Practices (GMP) to avoid enforcement actions from the FDA, which can include fines and withdrawal of approval[141]. - The European Union's pharmaceutical legislation revision is expected to start applying in mid-2028, impacting regulatory data exclusivity and environmental risk assessments[145]. - Companies must meet numerous regulatory requirements, including adverse event reporting and periodic report submissions, to maintain compliance with approved NDAs[146]. - Non-compliance with federal and state healthcare fraud and abuse laws can lead to significant civil and criminal penalties, including fines and exclusion from government healthcare programs[148]. - The company is subject to scrutiny under the federal Anti-Kickback Law, which prohibits certain financial arrangements that could influence healthcare purchasing decisions[147]. - The company must navigate complex privacy laws that vary by jurisdiction, complicating compliance efforts and increasing operational risks[149]. - The company may incur significant costs related to compliance with the Health Insurance Portability and Accountability Act (HIPAA) and other privacy regulations[152]. - Compliance with GDPR could result in fines up to EUR 20,000,000 or 4% of total worldwide annual turnover for serious offenses[156]. - The EU-U.S. Data Privacy Framework adopted in July 2023 allows for lawful transfer of personal data from the EU to the U.S.[157]. - Compliance with new AI regulations is expected to incur substantial costs in the future[158]. Market and Competitive Landscape - The market opportunity for an HBV curative regimen is significant, with over 250 million people worldwide suffering from cHBV infection[39]. - Current treatment options for chronic HBV infection include IFN and NA therapies, with less than 10% of patients achieving functional cure after treatment[40]. - The company faces competition from established pharmaceutical companies and research-stage companies, which may have greater resources and experience[109]. - The company’s ability to compete depends on successfully completing clinical trials, obtaining regulatory approvals, and effectively marketing approved products[112]. - Coverage and reimbursement for new drug products are uncertain and can vary significantly by country, potentially delaying market launches[159]. - Adverse pricing limitations may hinder the ability to recoup investments in product candidates even after obtaining marketing approval[160]. - Third-party payors may limit coverage to specific products, impacting the demand and pricing of approved drugs[161]. - The Medicaid Drug Rebate Program requires manufacturers to pay rebates for covered outpatient drugs, affecting revenue[164]. - The Inflation Reduction Act of 2022 established a Medicare Part B inflation rebate scheme, imposing penalties for non-compliance[167]. - The drug price negotiation program starting in 2026 may cap prices for certain high-spend drugs, impacting market conditions[169]. - Legislative changes aimed at cost containment could prevent or delay marketing approvals and affect profitability[171]. - Future revenues may be adversely affected by more rigorous coverage criteria and new payment methodologies resulting from healthcare reforms[179]. Financial Health and Future Outlook - The company has incurred an accumulated net deficit of approximately $1.4 billion from inception to December 31, 2025, and anticipates continued operating losses for the foreseeable future[198]. - The company does not expect to achieve operating profits until product sales, milestone payments, and royalty payments generate sufficient revenues to fund ongoing operations[198]. - Significant expenses related to ongoing operations and product candidate development are expected to continue, with potential delays and additional costs due to regulatory decisions and clinical trial challenges[199]. - The company may need to seek collaborators for product candidates at earlier stages or on less favorable terms due to financial constraints[200]. - The company does not anticipate generating significant revenues from product sales for the foreseeable future, if ever, and its ability to generate future revenues depends heavily on successful regulatory approvals[203]. - The company may require substantial additional capital to fund operations and development, with potential dilution to shareholders[192]. - The company faces risks related to compliance with foreign regulations, which could negatively impact operations and market access[180]. - The company may face substantial costs to ensure compliance with evolving privacy and data protection laws, including the GDPR and state-specific regulations[155].

Financial Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $91.5 million, a decrease from $122.6 million as of December 31, 2024 [6] - The company used $39.6 million in operating activities during 2025, which included one-time payments related to restructuring efforts [6] Revenue and Financial Performance - Total revenue for the year ended December 31, 2025, was $14.1 million, up from $6.2 million in 2024, primarily due to the recognition of previously deferred revenue from a partnership with Qilu Pharmaceutical [7] - The company reported a net loss of $33.5 million for 2025, compared to a net loss of $69.9 million in 2024, indicating improved financial performance [10] Operating Expenses - Research and development expenses decreased to $25.2 million in 2025 from $54.0 million in 2024, attributed to cost-saving measures and a focus on advancing clinical development [8] - General and administrative expenses also fell to $15.9 million in 2025 from $22.1 million in 2024, reflecting cost-cutting efforts [9] Clinical Developments - Two additional patients from Phase 2a clinical trials of imdusiran achieved functional cure for chronic hepatitis B (cHBV), bringing the total to ten patients [2][4] - Imdusiran is designed to reduce all hepatitis B viral proteins and antigens, with clinical trials showing it to be generally safe and well-tolerated [17] Legal and Settlement Updates - The company entered a settlement agreement with Moderna, resulting in a $950 million upfront payment and a potential additional $1.3 billion contingent payment [4] - The company is actively involved in ongoing litigation to protect its intellectual property related to lipid nanoparticle technology against Pfizer/BioNTech [4] Future Outlook - The company is evaluating a potential return of capital to shareholders in the third quarter of 2026, following the receipt of its portion of the noncontingent settlement payment from Moderna [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - Brand Engagement Network, Inc. (BNAI) is up 20% at $51.61 [3] - Latham Group, Inc. (SWIM) is up 20% at $7.79 [3] - Evolus, Inc. (EOLS) is up 14% at $4.74 [3] - Edesa Biotech, Inc. (EDSA) is up 11% at $4.86 [3] - 20/20 Biolabs, Inc. (AIDX) is up 11% at $3.28 [3] - DeFi Development Corp. (DFDV) is up 9% at $4.04 [3] - Accel Entertainment, Inc. (ACEL) is up 7% at $11.95 [3] - Solana Company (HSDT) is up 7% at $2.12 [3] - Nano-X Imaging Ltd. (NNOX) is up 6% at $2.76 [3] - Strive Asset Management, LLC (ASST) is up 5% at $8.81 [3] Premarket Losers - Battalion Oil Corporation (BATL) is down 28% at $19.67 [4] - TMD Energy Limited (TMDE) is down 24% at $3.03 [4] - Ascent Industries Co. (ACNT) is down 15% at $14.75 [4] - indie Semiconductor, Inc. (INDI) is down 14% at $2.71 [4] - WEBTOON Entertainment Inc. (WBTN) is down 13% at $9.98 [4] - STAAR Surgical Company (STAA) is down 10% at $17.00 [4] - Indonesia Energy Corporation Limited (INDO) is down 10% at $4.68 [4] - BiomX Inc. (PHGE) is down 7% at $4.52 [4] - Arbutus Biopharma Corporation (ABUS) is down 6% at $4.37 [4] - Global Interactive Technologies, Inc. (GITS) is down 6% at $2.43 [4]

Core Viewpoint - The company plans to appeal to a federal circuit court, asserting limited liability based on its status as a government contractor [1] Group 1 - The appeal is aimed at arguing the company's limited liability [1]

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4]. Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across any industry [4]. Legal and Patent Implications - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents, holding Moderna accountable for its unauthorized use of the technology [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3]. - Arbutus' CEO highlighted the transformative nature of the settlement and the recognition of their scientists' contributions to drug development [3]. Ongoing Litigation - Genevant continues its litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 vaccine sales [4]. Shareholder Actions - Roivant's board has approved a $1 billion share repurchase program, which includes a previously authorized $500 million [4][5].

Core Viewpoint - Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the unauthorized use of their lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2]. Settlement Details - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding the applicability of Section 1498 to Genevant's and Arbutus' claims [2][4]. - The settlement includes a judgment of infringement and no invalidity on four patents held by Genevant and Arbutus [4]. - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications and a covenant not to sue for certain patents and products [2][4]. Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their technology in addressing the pandemic [3]. - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development and the significance of the settlement for the company [3]. Financial Implications - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest across all industries [4]. - Arbutus is evaluating a potential return of capital to shareholders in conjunction with the upfront payment [4]. Ongoing Litigation - The litigation against Pfizer/BioNTech regarding the use of Arbutus' patented LNP technology in their COVID-19 vaccines is still ongoing [4].

Core Viewpoint - Roivant's subsidiary Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to the use of Genevant's and Arbutus' lipid nanoparticle (LNP) delivery technology in COVID-19 vaccines [1][2][4] Financial Summary - Moderna will pay $950 million upfront in July 2026 and an additional $1.3 billion contingent on a favorable appellate ruling regarding patent infringement claims [2][4] - If the contingent payment is realized, this settlement will be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [4] Legal and Licensing Details - The settlement includes a judgment of infringement and no invalidity on four Genevant/Arbutus patents [4] - Genevant will grant Moderna a global non-exclusive license to its LNP delivery technology for infectious disease applications, ending all patent-infringement litigation against Moderna related to its COVID-19 vaccines [2][4] Company Statements - Genevant's CEO expressed satisfaction with the settlement, emphasizing the importance of their LNP technology in addressing the COVID-19 pandemic [3] - Arbutus' CEO highlighted the recognition of their scientists' contributions to drug development through the invention of LNP delivery technology [3] Ongoing Litigation - Genevant continues litigation against Pfizer/BioNTech, whose Comirnaty sales account for approximately two-thirds of global COVID-19 mRNA vaccine sales [4]

分组1 - Arbutus Biopharma Corporation (ABUS) has experienced a decline of approximately 10% in its stock price over the past month due to a patent dispute with Moderna [1] - The company is involved in the biotechnology sector, focusing on innovative drug development and unique therapeutic approaches [1] - The analyst emphasizes the importance of evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities while considering financial fundamentals [1]

Core Viewpoint - Arbutus Biopharma (ABUS) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates indicate an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [10]. Specifics on Arbutus - For the fiscal year ending December 2025, Arbutus is expected to earn -$0.19 per share, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Arbutus has increased by 5.9%, reflecting positive sentiment among analysts [8].